4582 — SymBio Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: SymBio Pharmaceuticals says exercise of options
Brief: SymBio Pharmaceuticals says exercise of options
Brief: SymBio Pharmaceuticals says exercise of options
Table: SymBio Pharmaceuticals - Q1 parent results
Brief: SymBio Pharmaceuticals says termination of development of patient-controlled pain management drug "SyB P-1501"
Table: SymBio Pharmaceuticals -2017 parent results
Brief: Symbio Pharmaceuticals initiated Phase 1 Study in Japan for Oral Treakisym in patients with progressive solid tumors
Brief: SymBio Pharmaceuticals says arbitration against The Medicines Company
Table: SymBio Pharmaceuticals - 9-MTH parent results
Table: SymBio Pharmaceuticals -2017 parent forecast
Brief: Eagle Pharmaceuticals licenses Japanese rights for Bendamustine HCl
Brief: SymBio Pharmaceuticals commences phase III clinical trial for TREAKISYM
Table: SymBio Pharmaceuticals - 6-MTH parent results
Table: SymBio Pharmaceuticals - Q1 parent results
Table: SymBio Pharmaceuticals -2016 parent results
Table: SymBio Pharmaceuticals -9-MTH parent results
Brief: SymBio Pharmaceuticals says investment limited partnership cuts stake in it to 3.6 pct
Brief: SymBio Pharmaceuticals says approval in Japan of anti-cancer drug TREAKISYM intravenous infusion 25 mg
Table: SymBio Pharmaceuticals -6-MTH parent results